Annual SG&A
$12.52 B
+$324.00 M+2.66%
31 December 2023
Summary:
Novartis AG annual selling, general & administrative expenses is currently $12.52 billion, with the most recent change of +$324.00 million (+2.66%) on 31 December 2023. During the last 3 years, it has fallen by -$1.68 billion (-11.83%). NVS annual SG&A is now -30.65% below its all-time high of $18.05 billion, reached on 31 December 2011.NVS Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$3.13 B
+$43.00 M+1.39%
30 September 2024
Summary:
Novartis AG quarterly selling, general & administrative expenses is currently $3.13 billion, with the most recent change of +$43.00 million (+1.39%) on 30 September 2024. Over the past year, it has increased by +$43.00 million (+1.39%). NVS quarterly SG&A is now -34.75% below its all-time high of $4.80 billion, reached on 31 December 2011.NVS Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$46.29 B
0.00%
30 September 2024
Summary:
Novartis AG TTM selling, general & administrative expenses is currently $46.29 billionOver the past year, it has increased by +$34.04 billion (+277.71%). NVS TTM SG&A is now -51.35% below its all-time high of $18.05 billion, reached on 31 December 2011.NVS TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVS Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.7% | +1.4% | +277.7% |
| 3 y3 years | -11.8% | -13.4% | +212.3% |
| 5 y5 years | -8.8% | -11.7% | +227.4% |
NVS Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -11.8% | +2.7% | -13.4% | +62.7% | at high | +9.3% |
| 5 y | 5 years | -12.9% | +2.7% | -20.1% | +62.7% | at high | +9.3% |
| alltime | all time | -30.6% | +80.3% | -34.8% | +107.7% | -51.4% | +94.0% |
Novartis AG Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.13 B(+1.4%) | $12.51 B(+0.3%) |
| June 2024 | - | $3.09 B(+8.8%) | $12.47 B(0.0%) |
| Mar 2024 | - | $2.84 B(-17.5%) | $12.47 B(-0.4%) |
| Dec 2023 | $12.52 B(+2.7%) | $3.44 B(+11.4%) | $12.52 B(+2.1%) |
| Sept 2023 | - | $3.09 B(0.0%) | $12.26 B(+1.3%) |
| June 2023 | - | $3.09 B(+6.9%) | $12.10 B(-3.9%) |
| Mar 2023 | - | $2.89 B(-9.2%) | $12.59 B(-4.7%) |
| Dec 2022 | $12.19 B(-4.9%) | $3.18 B(+8.4%) | $13.21 B(+10.5%) |
| Sept 2022 | - | $2.94 B(-18.0%) | $11.96 B(-5.4%) |
| June 2022 | - | $3.58 B(+2.0%) | $12.64 B(-1.4%) |
| Mar 2022 | - | $3.51 B(+82.3%) | $12.81 B(-0.1%) |
| Dec 2021 | $12.83 B(-9.6%) | $1.93 B(-46.8%) | $12.83 B(-13.5%) |
| Sept 2021 | - | $3.62 B(-3.6%) | $14.82 B(+1.4%) |
| June 2021 | - | $3.75 B(+6.4%) | $14.63 B(+2.7%) |
| Mar 2021 | - | $3.53 B(-10.1%) | $14.24 B(+0.3%) |
| Dec 2020 | $14.20 B(-1.2%) | $3.92 B(+14.8%) | $14.20 B(+0.1%) |
| Sept 2020 | - | $3.42 B(+1.5%) | $14.18 B(-0.9%) |
| June 2020 | - | $3.37 B(-3.4%) | $14.31 B(-1.5%) |
| Mar 2020 | - | $3.49 B(-10.7%) | $14.53 B(+1.1%) |
| Dec 2019 | $14.37 B(+4.8%) | $3.90 B(+10.0%) | $14.37 B(+1.6%) |
| Sept 2019 | - | $3.55 B(-1.0%) | $14.14 B(+2.1%) |
| June 2019 | - | $3.58 B(+7.7%) | $13.85 B(+0.7%) |
| Mar 2019 | - | $3.33 B(-9.4%) | $13.76 B(+0.3%) |
| Dec 2018 | $13.72 B(+10.0%) | $3.68 B(+12.8%) | $13.72 B(+18.8%) |
| Sept 2018 | - | $3.26 B(-6.7%) | $11.55 B(-3.5%) |
| June 2018 | - | $3.50 B(+6.4%) | $11.97 B(-2.5%) |
| Mar 2018 | - | $3.28 B(+117.6%) | $12.28 B(-1.5%) |
| Dec 2017 | $12.46 B(-12.2%) | $1.51 B(-59.0%) | $12.46 B(-15.7%) |
| Sept 2017 | - | $3.68 B(-3.4%) | $14.79 B(+1.9%) |
| June 2017 | - | $3.81 B(+9.6%) | $14.52 B(+1.1%) |
| Mar 2017 | - | $3.47 B(-9.5%) | $14.36 B(+1.2%) |
| Dec 2016 | $14.19 B(-0.4%) | $3.84 B(+12.9%) | $14.19 B(-0.3%) |
| Sept 2016 | - | $3.40 B(-6.8%) | $14.24 B(-0.4%) |
| June 2016 | - | $3.65 B(+10.4%) | $14.30 B(+0.2%) |
| Mar 2016 | - | $3.31 B(-14.9%) | $14.27 B(+0.2%) |
| Dec 2015 | $14.25 B(-5.0%) | $3.88 B(+12.2%) | $14.25 B(-0.6%) |
| Sept 2015 | - | $3.46 B(-4.3%) | $14.33 B(-0.7%) |
| June 2015 | - | $3.62 B(+10.2%) | $14.43 B(-1.4%) |
| Mar 2015 | - | $3.28 B(-17.2%) | $14.64 B(-2.4%) |
| Dec 2014 | $14.99 B(-1.6%) | $3.96 B(+11.2%) | $14.99 B(-1.2%) |
| Sept 2014 | - | $3.56 B(-6.8%) | $15.17 B(-0.7%) |
| June 2014 | - | $3.83 B(+5.2%) | $15.28 B(+0.3%) |
| Mar 2014 | - | $3.64 B(-12.3%) | $15.24 B(-3.7%) |
| Dec 2013 | $15.24 B(+0.8%) | $4.15 B(+12.8%) | $15.82 B(+11.9%) |
| Sept 2013 | - | $3.67 B(-2.9%) | $14.14 B(-2.8%) |
| June 2013 | - | $3.78 B(-10.3%) | $14.55 B(-3.7%) |
| Mar 2013 | - | $4.22 B(+71.0%) | $15.12 B(+0.0%) |
| Dec 2012 | $15.12 B | $2.47 B(-39.6%) | $15.12 B(-13.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $4.09 B(-6.1%) | $17.45 B(-1.7%) |
| June 2012 | - | $4.35 B(+3.2%) | $17.75 B(-1.6%) |
| Mar 2012 | - | $4.21 B(-12.3%) | $18.05 B(-0.0%) |
| Dec 2011 | $18.05 B(+14.3%) | $4.80 B(+9.5%) | $18.05 B(+0.1%) |
| Sept 2011 | - | $4.39 B(-5.5%) | $18.03 B(+3.7%) |
| June 2011 | - | $4.64 B(+10.1%) | $17.39 B(+5.8%) |
| Mar 2011 | - | $4.22 B(-11.8%) | $16.43 B(+4.0%) |
| Dec 2010 | $15.80 B(+10.2%) | $4.78 B(+27.9%) | $15.80 B(+4.1%) |
| Sept 2010 | - | $3.74 B(+1.4%) | $15.18 B(+2.3%) |
| June 2010 | - | $3.69 B(+2.9%) | $14.85 B(+1.1%) |
| Mar 2010 | - | $3.58 B(-14.0%) | $14.69 B(+2.5%) |
| Dec 2009 | $14.33 B(+1.7%) | $4.17 B(+22.4%) | $14.33 B(+3.5%) |
| Sept 2009 | - | $3.40 B(-3.6%) | $13.85 B(-0.1%) |
| June 2009 | - | $3.53 B(+9.5%) | $13.86 B(-1.0%) |
| Mar 2009 | - | $3.23 B(-12.4%) | $13.99 B(-0.8%) |
| Dec 2008 | $14.10 B(+6.3%) | $3.68 B(+7.8%) | $14.10 B(+0.0%) |
| Sept 2008 | - | $3.42 B(-6.8%) | $14.09 B(+1.7%) |
| June 2008 | - | $3.67 B(+9.9%) | $13.86 B(+2.5%) |
| Mar 2008 | - | $3.33 B(-9.4%) | $13.52 B(+2.0%) |
| Dec 2007 | $13.26 B(+10.7%) | $3.68 B(+15.7%) | $13.26 B(+1.4%) |
| Sept 2007 | - | $3.18 B(-4.4%) | $13.08 B(+2.0%) |
| June 2007 | - | $3.33 B(+8.4%) | $12.82 B(+2.9%) |
| Mar 2007 | - | $3.07 B(-12.2%) | $12.46 B(+3.1%) |
| Dec 2006 | $11.97 B(+12.6%) | $3.50 B(+19.6%) | $12.08 B(+11.8%) |
| Sept 2006 | - | $2.92 B(-1.4%) | $10.81 B(+1.0%) |
| June 2006 | - | $2.96 B(+9.9%) | $10.71 B(+0.9%) |
| Mar 2006 | - | $2.70 B(+21.2%) | $10.61 B(-0.2%) |
| Dec 2005 | $10.63 B(+6.4%) | $2.23 B(-21.1%) | $10.63 B(-2.8%) |
| Sept 2005 | - | $2.82 B(-1.6%) | $10.94 B(+3.3%) |
| June 2005 | - | $2.87 B(+5.4%) | $10.58 B(+2.8%) |
| Mar 2005 | - | $2.72 B(+7.6%) | $10.29 B(+0.6%) |
| Dec 2004 | $9.99 B(+8.2%) | $2.53 B(+2.3%) | $10.24 B(+1.9%) |
| Sept 2004 | - | $2.47 B(-4.1%) | $10.04 B(+1.1%) |
| June 2004 | - | $2.58 B(-3.2%) | $9.94 B(+2.1%) |
| Mar 2004 | - | $2.66 B(+14.1%) | $9.73 B(+5.4%) |
| Dec 2003 | $9.23 B(+17.2%) | $2.33 B(-1.2%) | $9.23 B(+4.1%) |
| Sept 2003 | - | $2.36 B(-0.5%) | $8.87 B(+5.1%) |
| June 2003 | - | $2.37 B(+9.7%) | $8.44 B(+2.8%) |
| Mar 2003 | - | $2.16 B(+9.9%) | $8.21 B(+35.8%) |
| Dec 2002 | $7.88 B(+10.0%) | $1.97 B(+2.0%) | $6.04 B(+48.3%) |
| Sept 2002 | - | $1.93 B(-9.9%) | $4.07 B(+90.1%) |
| June 2002 | - | $2.14 B(+24.6%) | $2.14 B(+24.6%) |
| Dec 2001 | $7.17 B(-11.2%) | - | - |
| June 2001 | - | $1.72 B(+4.4%) | $1.72 B(+4.4%) |
| Dec 2000 | $8.07 B(+16.3%) | - | - |
| June 2000 | - | $1.65 B | $1.65 B |
| Dec 1999 | $6.94 B(-11.8%) | - | - |
| Dec 1998 | $7.87 B | - | - |
FAQ
- What is Novartis AG annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Novartis AG?
- What is Novartis AG annual SG&A year-on-year change?
- What is Novartis AG quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Novartis AG?
- What is Novartis AG quarterly SG&A year-on-year change?
- What is Novartis AG TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Novartis AG?
- What is Novartis AG TTM SG&A year-on-year change?
What is Novartis AG annual selling, general & administrative expenses?
The current annual SG&A of NVS is $12.52 B
What is the all time high annual SG&A for Novartis AG?
Novartis AG all-time high annual selling, general & administrative expenses is $18.05 B
What is Novartis AG annual SG&A year-on-year change?
Over the past year, NVS annual selling, general & administrative expenses has changed by +$324.00 M (+2.66%)
What is Novartis AG quarterly selling, general & administrative expenses?
The current quarterly SG&A of NVS is $3.13 B
What is the all time high quarterly SG&A for Novartis AG?
Novartis AG all-time high quarterly selling, general & administrative expenses is $4.80 B
What is Novartis AG quarterly SG&A year-on-year change?
Over the past year, NVS quarterly selling, general & administrative expenses has changed by +$43.00 M (+1.39%)
What is Novartis AG TTM selling, general & administrative expenses?
The current TTM SG&A of NVS is $46.29 B
What is the all time high TTM SG&A for Novartis AG?
Novartis AG all-time high TTM selling, general & administrative expenses is $18.05 B
What is Novartis AG TTM SG&A year-on-year change?
Over the past year, NVS TTM selling, general & administrative expenses has changed by +$34.04 B (+277.71%)